Veradermics, Inc. has announced significant progress in its clinical development pipeline with the release of positive topline data from Part B of its Phase 2/3 clinical trial, Study ‘302’. This trial evaluated VDPHL01, an investigational treatment for mild-to-moderate pattern hair loss in males. The results could strengthen Veradermics’ position in the competitive pharmaceutical preparations industry.
On November 9, 2026, the company disclosed that the trial enrolled 519 participants, who were randomized to receive either VDPHL01 in different dosages or a placebo over a six-month period. The data indicates that participants in the treatment groups experienced a significant increase in non-vellus hair count, suggesting potential efficacy in promoting hair growth.
Background
Veradermics, Inc., incorporated in Delaware, operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the New York Stock Exchange under the ticker MANE. With a focus on developing innovative treatments, Veradermics aims to address unmet medical needs in the hair restoration market. Recent filings include an 8-K on November 9, 2026, detailing the latest trial results.
What the Filing Says
The filing states, “In Part B of Study ‘302’, participants in the VDPHL01 continued group had an increase in non-vellus hair count of 43.9 hairs/cm2 and 29.7 hairs/cm2 in twice-daily (BID) and once-daily (QD) treatment arms from baseline to Month 12, respectively.” Additionally, 89.1% of participants in the BID arm and 79.8% in the QD arm reported visible improvement in hair coverage.
Impact
This announcement may significantly impact Veradermics’ future, as it positions the company favorably against competitors in the hair loss treatment market. The promising results could attract investor interest and pave the way for further clinical trials and potential regulatory approvals. Stakeholders, including investors and healthcare professionals, will be closely monitoring the company’s next steps in bringing VDPHL01 to market.
What's Next
The filing does not specify the next steps following this announcement, but the positive results from the trial are likely to lead to further discussions regarding the drug's potential commercialization and additional studies.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




